Russian drug co inks deal with Bayer HealthCare
Russian drug company Medsintez and Bayer HealthCare has signed strategic partnerships to jointly manufacture and commercialize diagnostic imaging products as well pharmaceuticals to treat neural disorders and infections.
Both the companies also aim to cooperate in the research, development and production of new substances and medicines. They also aim to accelerate the access to innovative pharmaceuticals for Russian patients.
The joint marketing activities are scheduled to commence next year.
Andreas Fibig, President of Bayer HealthCare Pharmaceuticals said, “The local production of our products will provide additional momentum to our business development in this growth market.” He also said, “It will ultimately serve our customers, patients, and doctors in Russia and thus strengthen our competitive position.”
Both these companies will also begin their cooperation with full cycle manufacturing of the anti-infectives Avelox and Ciprobay diagnostic imaging products as well as Nimotop for treating neural disorders in the existing as well as new facilities.
Alexey Podkorytoy, CEO of Medsintez said, “Medsintez and Bayer Healthcare will provide top quality products to the market, according to international standards.” Mr. Alexey also said, “In addition, the future research partnership with Bayer HealthCare will allow us to launch new drugs based on molecules developed by Russian research companies to the global market.”
Bayer Healthcare is a global enterprise with competencies in the fields of healthcare, agriculture, and high-tech materials. The aim of the company is to discover, develop, manufacture and market products which will improve human and animal health worldwide.
Medsintez is a Russian company with business interests in the fields of production of medical equipment and devices as well as pharmaceuticals.
